@article{ff60e5bd79db44e2acea2090f61c1564,
title = "The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers",
abstract = "Adenosine-to-inosine (A-to-I) RNA editing is a widespread post-transcriptional mechanism, but its genomic landscape and clinical relevance in cancer have not been investigated systematically. We characterized the global A-to-I RNA editing profiles of 6,236 patient samples of 17 cancer types from The Cancer Genome Atlas and revealed a striking diversity of altered RNA-editing patterns in tumors relative to normal tissues. We identified an appreciable number of clinically relevant editing events, many of which are in noncoding regions. We experimentally demonstrated the effects of several cross-tumor nonsynonymous RNA editing events on cell viability and provide the evidence that RNA editing could selectively affect drug sensitivity. These results highlight RNA editing as an exciting theme for investigating cancer mechanisms, biomarkers, and treatments.",
author = "Leng Han and Lixia Diao and Shuangxing Yu and Xiaoyan Xu and Jie Li and Rui Zhang and Yang Yang and Werner, {Henrica M.J.} and Eterovic, {A. Karina} and Yuan Yuan and Jun Li and Nikitha Nair and Rosalba Minelli and Tsang, {Yiu Huen} and Cheung, {Lydia W.T.} and Jeong, {Kang Jin} and Jason Roszik and Zhenlin Ju and Woodman, {Scott E.} and Yiling Lu and Scott, {Kenneth L.} and Li, {Jin Billy} and Mills, {Gordon B.} and Han Liang",
note = "Funding Information: We gratefully acknowledge contributions from TCGA Research Network and TCGA Pan-Cancer Analysis Working Group. This study was supported by the National Institutes of Health (grants CA168394, CA098258, and U24CA143883 to G.B.M.; grants CA098258 Career Development Award and R01CA175486 to H.L.; grant R01GM102484 to J.B.L.; and Cancer Center Support Grant CA016672); the R. Lee Clark Fellow Award from The Jeanne F. Shelby Scholarship Fund (to H.L.); a grant from the Cancer Prevention and Research Institute of Texas (RP140462 to H.L.); the Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine (to H.L.); the Adelson Medical Research Foundation (to G.B.M.); and the Ellison Medical Foundation (to J.B.L.). We thank the MD Anderson high-performance computing core facility for computing and LeeAnn Chastain for editorial assistance. G.B.M. has sponsored research support from AstraZeneca and is on the scientific advisory boards for AstraZeneca, ImmunoMet, Nuevolution, and Precision Medicine. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",
year = "2015",
month = oct,
day = "12",
doi = "10.1016/j.ccell.2015.08.013",
language = "English (US)",
volume = "28",
pages = "515--528",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",
}